Small Methods,
Journal Year:
2024,
Volume and Issue:
8(11)
Published: Sept. 25, 2024
Abstract
Despite
the
advent
of
various
medical
interventions
for
cancer
treatment,
disease
continues
to
pose
a
formidable
global
health
challenge,
necessitating
development
new
therapeutic
approaches
more
effective
treatment
outcomes.
Photodynamic
therapy
(PDT),
which
utilizes
light
activate
photosensitizer
produce
cytotoxic
reactive
oxygen
species
(ROS)
eradicating
cells,
has
emerged
as
promising
approach
due
its
high
spatiotemporal
precision
and
minimal
invasiveness.
However,
widespread
clinical
use
PDT
faces
several
challenges,
including
inefficient
production
ROS
in
hypoxic
tumor
microenvironment,
limited
penetration
depth
biological
tissues,
inadequate
accumulation
photosensitizers
at
site.
Over
past
decade,
there
been
increasing
interest
utilization
photofunctional
transition
metal
complexes
applications
their
intriguing
photophysical
photochemical
properties.
This
review
provides
an
overview
current
design
strategies
used
innovative
phototherapeutics,
aiming
address
limitations
associated
with
achieve
The
challenges
future
perspectives
on
translation
are
also
discussed.
ChemPhotoChem,
Journal Year:
2025,
Volume and Issue:
unknown
Published: May 1, 2025
The
near
infrared
(NIR)
optical
window
enables
to
observe
biological
tissue
noninvasively
through
photoimaging
using
luminophores.
Particularly,
the
light
in
NIR
II
region
of
1000–1400
nm
between
strong
absorption
bands
H
2
O
and
chromophores
is
advantageous
for
phototherapies
deep
tissue.
Pt
complexes
possessing
high
emission
ability
luminescence
tunability
are
expected
be
luminophores
imaging
photosensitizers
photodynamic
therapy.
Herein,
from
designed
by
strategy
extension
ligand
π
conjugation
aggregation
Pt–Pt
interaction
recent
works
reviewed.
Journal of the American Chemical Society,
Journal Year:
2025,
Volume and Issue:
147(9), P. 7161 - 7181
Published: Feb. 20, 2025
Photocatalytic
cancer
therapy
(PCT)
has
emerged
as
a
cutting-edge
anticancer
mechanism
of
action,
harnessing
light
energy
to
mediate
the
catalytic
oxidation
intracellular
substrates.
PCT
is
significant
current
importance
due
its
potential
address
limitations
conventional
chemotherapy,
particularly
drug
resistance
and
side
effects.
This
approach
offers
noninvasive,
targeted
treatment
option
by
utilizing
metal-based
photocatalysts
induce
redox
metabolic
disorders
within
cells.
The
disrupt
cell
metabolism
converting
NADH/NAD(P)H
NAD+/NAD(P)+
via
photoredox
processes,
altering
NAD+/NADH
or
NAD(P)+/NAD(P)H
ratios,
which
are
crucial
for
cellular
metabolism.
Ir(III),
Ru(II),
Re(I),
Os(II)
demonstrated
promising
efficacy.
Despite
these
developments,
gaps
remain
in
literature
translating
this
new
into
clinical
trials.
Perspective
critically
examines
developments
research
area
provides
future
directions
designing
efficient
PCT.
Inorganics,
Journal Year:
2025,
Volume and Issue:
13(5), P. 156 - 156
Published: May 8, 2025
Towards
the
efforts
to
expand
bioactivity
and
reduce
toxic
adverse
properties
of
known
metal-based
drugs,
various
multinuclear
complexes
have
recently
been
studied.
They
shown
enhancement
target
specificity
selectivity.
Different
from
small
organic
compounds
traditional
with
anticancer
activity,
iridium(III)
or
heteronuclear
metallodrugs
confirmed
potential
advantages
due
their
unique
biological
chemical
diversities,
better
activity
different
mechanisms.
Ir(III)
coordination
compounds,
similar
most
Pt
group
are
excessive
interest
because
cytotoxic
effective
cellular
uptake
tolerance
by
healthy
cells.
Although
mononuclear
complex
extensively
studied
as
promising
candidates
for
antitumor
application,
research
on
antineoplastic
homo-
hetero-multinuclear
is
not
abundant;
nevertheless,
intensive
investigations
conducted
in
recent
years
towards
developing
that
anticipated
improved
therapeutic
biotarget
Multimetallic
frameworks
offered
interesting
possibilities
designing
new
agents
exploiting
action
metal
cations
at
same
time.
This
method
was
very
successful
design
cyclometalated
half-sandwich
organometallic
compounds.
In
described
background,
many
homonuclear
estimated
exposed
cancer
therapy.
review
intends
summarize
newly
reported
innovative
Ir(III)-based
afford
a
wide-ranging
overview
current
development
perspectives
practical
impact
these
tumor
therapy
field.
It
this
analysis
will
provide
significant
direction
further
progress
active
iridium-based
agents.
Journal of Medicinal Chemistry,
Journal Year:
2024,
Volume and Issue:
67(15), P. 13435 - 13445
Published: July 30, 2024
Photodynamic
therapy
has
been
regarded
as
a
noninvasive
treatment
for
cancer
with
spatiotemporal
control
over
drug
activation.
Bis-terpyridyl
Ru(II)
complexes
exhibit
promising
achiral
structure
but
suffer
from
low
photoreactivity
due
to
deviation
the
ideal
octahedral
geometry.
Herein,
we
introduce
donor–acceptor–donor
motif
construct
dinuclear
bis-terpyridyl
complex
(Ru2).
Ru2
exhibits
superior
light
absorption
properties
compared
mononuclear
Ru1.
Importantly,
upon
595
nm
excitation,
shows
synergetic
type
I/II
photosensitization
and
photocatalytic
activity,
while
Ru1
is
inactive.
Anticancer
mechanistic
studies
reflect
that
induces
intracellular
redox
imbalance
affects
biosynthetic
metabolic
processes,
leading
cell
apoptosis.
Overall,
this
work
provides
simple
strategy
rouse
PDT
efficiency
of
complexes.
Applied Organometallic Chemistry,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Nov. 14, 2024
ABSTRACT
We
developed
a
novel
hetero‐bimetallic
Fe(III)‐Mn(I)
complex
by
combining
hydroxyl
radicals
generating
Fe(III)‐Phenolato/Carboxylato
and
CO‐releasing
Mn(I)(CO)
3
complexes
to
achieve
dual‐modality
theranostic
tool
for
photoactivated
anticancer
therapy.
were
conjugated
through
the
amide
coupling
synthesize
bimetallic
(
[Fe‐Mn]
)
characterized
analytically
spectroscopically.
Various
photophysical
assays
have
confirmed
production
of
release
CO
when
biologically
benign
[
Fe‐Mn
]
is
activated
visible
light
(400–700
nm),
resulting
in
significant
increase
luminescence
intensity.
The
cytotoxic
potential
complex,
resulted
from
enrichment
ROS
A549
cells
with
photoindex
~35
leaving
HPL1D
unaffected.
probed
caspase
3/7‐dependent
apoptosis
on
photoactivation
vitro.
([
Fe‐Mn]
provides
an
ideal
example
next‐generation
ChemMedChem,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Nov. 4, 2024
Abstract
Photo‐induced
chemotherapy
offers
the
best
option
for
selective
treatment
of
cancer
among
all
prevailing
modalities.
Iridium
(III)
complexes,
flourished
with
excellent
photophysical
and
photochemical
properties,
have
been
considered
to
be
superior
undergoing
photo‐responsive
therapy.
Large
Stokes
shift,
long‐lived
triplet
excited
state,
photostability,
tuneable
emission
rendered
its
excellence
as
a
phototheranostic
agent.
In
particular,
cyclometalated
Ir
complexes
their
respective
nanoparticles
made
strong
niche
in
arena
recent
years,
based
shown
promising
utilities
both
imaging
therapeutic
agents
well.
Therefore,
this
review
summarises
advances
strategic
designing
Ir(III)
augment
applications
precision
medicine.
